Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Doxorubicin in Desmoid Tumor
NCT05561036Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2020
- Primary completion
- Dec 2022
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pegylated liposomal doxorubicin in desmoid tumor (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
desmoid tumor
Beyond the preview
Go deeper on NCT05561036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05561036.